Alluvi, formerly BI 4744, represents a promising development in weight control therapy. This dual agonist targeting both glucagon-like peptide-1 and GIP sites demonstrates compelling effectiveness in patient https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/